Drug Profile
Typhoid conjugate vaccine - International Vaccine Institute/Incepta/SK Bioscience/PT Biofarma
Alternative Names: NBP-618; SKYTyphoid®; Typhoid-vaccine-Vi-DT-conjugate; Vi-DT; Vi-DT conjugated typhoid vaccine; Vi-DT Typhoid Conjugate VaccineLatest Information Update: 25 Sep 2022
Price :
$50
*
At a glance
- Originator International Vaccine Institute
- Developer Incepta Vaccine; International Vaccine Institute; PT Bio Farma; SK Bioscience
- Class Bacterial vaccines; Conjugate vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Typhoid
Most Recent Events
- 25 Sep 2022 No development reported - Phase-III for Typhoid (In adolescents, In children, In infants, Prevention, In adults) in Nepal (IM)
- 22 Sep 2022 Phase-III development is ongoing Philppines and Indonesia
- 01 Dec 2021 PT Bio Farma completes Phase-III clinical trials in Typhoid (In adolescents, In children, In infants, Prevention, In adults) in Indonesia (IM) (NCT04051268)